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ABSTRACT
Objective: To examine the recorded indication for
antipsychotic prescriptions in UK primary care.
Design: Cohort study.
Setting: Primary care.
Participants: Individuals prescribed antipsychotics
between 2007 and 2011.
Measures: The proportion of individuals prescribed
antipsychotics with a diagnosis of (1) psychosis and
bipolar disorder, (2) other diagnoses including depression,
anxiety and dementia and (3) none of these diagnoses.
Results:We identified 47 724 individuals prescribed
antipsychotic agents. 13 941 received first-generation
agents and 27 966 received second-generation agents.
The rates of prescribing were higher in females (incidence
rate ratio (IRR) 1.092 (95% CI 1.088 to 1.095), older
people (80+ vs 40–49; IRR 2.234 (2.222 to 2.246)) and in
those from the most deprived areas (most deprived vs least
deprived IRR 3.487 (3.567 to 3.606). Of those receiving
first-generation antipsychotics, less than 50% had a
diagnosis of psychosis/bipolar disorder. For the second-
generation agents, the numbers ranged from 4824 (36%)
for quetiapine to 7094 (62%) for olanzapine. In patients
without psychosis/bipolar disorder, common diagnoses
included anxiety, depression, dementia, sleep and
personality disorders. For example, in risperidone users,
14% had an anxiety code, 22% depression, 12%
dementia, 11% sleep disorder and 4% personality
disorder. The median daily doses and duration of treatment
were greater in those with schizophrenia (eg, risperidone
median daily dose 4 mg; IQR 2–6: median duration
1.2 years) than in those with non-psychotic/bipolar
disorders such as depression or anxiety (eg, risperidone
1 mg; IQR 1–2: 0.6 years). A relatively large proportion
(between 6% and 17%) of people receiving individual
antipsychotics had none of the diagnoses stated above.
Conclusions: In UK primary care, a large proportion of
people prescribed antipsychotics have no record of
psychotic or bipolar disorder. They are often older people
with conditions including dementia, non-psychotic
depression, anxiety and sleep disorders.
BACKGROUND
Antipsychotic medications are the ﬁrst-line
pharmacological intervention for severe
mental illnesses (SMI) such as schizophrenia
and other psychoses. However, they are also
increasingly prescribed for the treatment of
bipolar affective disorder. They are not rou-
tinely recommended for other mental health
conditions such as depression, sleep disorders
or obsessive compulsive disorder (OCD).
There is concern about rates of antipsychotic
prescribing in dementia since they may be
associated with increased rates of strokes
and all-cause mortality.1 2 Prescription of anti-
psychotics requires caution given their associ-
ation with a range of serious adverse effects
including extra-pyramidal side effects with
ﬁrst-generation agents, weight gain and lipid/
glucose dysregulation with second-generation
Strengths and limitations of this study
We determined the likely indication for antipsychotic
prescriptions in a large, representative sample of
people in UK primary care. The data source con-
tained accurate prescribing information, although
prescriptions issued in secondary care would not
have been captured. Diagnoses of severe mental ill-
nesses have been validated in primary care. The
nature of the data did not allow us to determine the
clinicians’ rationale for prescribing antipsychotics to
people without psychoses or bipolar disorder
diagnoses.
▪ Less than half of the people prescribed the most
common first-generation antipsychotics in UK
primary care have a diagnosis of psychosis or
bipolar disorder.
▪ Findings were similar for second-generation
agents, although 62% of people receiving olanza-
pine did have a diagnosis of psychosis or bipolar
disorder.
▪ These agents are more commonly prescribed to
older people, despite the propensity of this age
group to develop side effects.
▪ Antipsychotics are still commonly prescribed to
people with a diagnosis of dementia, contrary to
clinical guidance, and this needs further attention
in UK primary care.
▪ Other common diagnoses included depression,
anxiety disorders, personality disorders and atten-
tion deficit hyperactivity disorder (ADHD), while up
to 17% of people receiving antipsychotics had
none of the diagnoses we explored.
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agents. International guidelines stress the importance of
regular monitoring of body mass index (BMI), glucose
and lipids in people receiving repeat prescriptions of
these agents, given their propensity to affect these
parameters.
National guidelines do recommend antipsychotics for
the relatively rare condition of psychotic depression and
as a possible intervention for treatment-resistant cases of
severe depression3 and OCD4. In clinical practice, these
agents may be prescribed ‘off-label’ for patients who do
not have a diagnosis of SMI in their clinical notes. They
are sometimes used to augment antidepressants in
complex or treatment-resistant cases of OCD, anxiety
and personality disorders. Although antipsychotics may
be used in sleep disorders, treatment guidelines do not
recommend using such agents on account of their side
effect proﬁles.5 Guidelines for borderline personality
disorder recommend that short-term treatment with
antipsychotics (up to a week) may be beneﬁcial in crisis
situations or when comorbid psychotic symptoms occur.6
Our aim was to examine the recorded indication for
antipsychotic prescriptions in UK primary care. Further,
we sought to describe the prescribing pattern by diag-
nostic group.
Objectives
1. To examine the likely indications for antipsychotic
prescribing in UK primary care.
2. To describe the prescribing patterns (duration of treat-
ment and average dose) in three broad groups of
people who may receive antipsychotics in primary care:
A. Those with a diagnosis of SMI (psychosis or
bipolar disorder);
B. Those without a diagnosis of SMI, but with a
mental health diagnosis such as depression,
personality disorder or dementia;
C. Individuals with none of these conditions in
their general practice notes.
METHOD
Study design
Cohort study.
Setting
Primary care in the UK.
Data source
We used data from The Health Improvement Network
(THIN),7 a UK primary care database like Clinical
Practice Research Datalink (CPRD),8 which is based on
data from routine clinical care and administration.
THIN data, like those from the CPRD, are derived from
practices using Vision software and are available anonym-
ously for research.9 The database includes demographics
and the Townsend deprivation quintile. The latter is a
validated measure of social deprivation, attributed to the
patient’s geographical postcode, covering a small area of
approximately 150 households.10 Data such as diagnoses
and symptoms are entered as Read codes, a hierarchical
classiﬁcation system.11 The database also includes records
of all prescriptions issued and these are linked to the
British National Formulary (BNF).12 The exception to
this is clozapine, which is almost exclusively prescribed
and monitored in hospital outpatient clinics. Prescribing
is well recorded in THIN because all prescriptions from
general practice are generated via the computerised
system. This information produces a longitudinal record
for each individual in the database. Ninety-eight per cent
of the UK population is registered with a general prac-
tice9; THIN is representative of the UK population in
general in terms of their demographic characteristics13
and practices are geographically spread across the UK. At
the time of this study, the full database included almost
10 million patients. For quality purposes, data were
extracted only after the date when there was evidence
that general practices were using their computer system
fully (acceptable computer use (ACU) dates14) and mor-
tality were adequately recorded (acceptable mortality rate
(AMR)15).
Participants
We initially included all people who had received at least
one prescription for any antipsychotic medication after 1
January 2007 or after the date at which practice met
quality standards. The follow-up ended at the earliest of
date of (1) death, (2) transferring out of the practice, (3)
last data collection from the practice, (4) reaching the
age of 100 years or (5) 31 December 2011. The start of
follow-up for each individual was the date of the ﬁrst anti-
psychotic prescription during these periods. We excluded
individuals with less than 6 months of follow-up data.
Antipsychotic data
First, we determined the overall rates of prescribing of
all ﬁrst-generation and second-generation antipsychotics
in UK primary care (see online supplementary appendix
2 for the full list of ﬁrst-generation and second-
generation antipsychotics). Subsequently, we focused on
the three most commonly prescribed ﬁrst-generation
(haloperidol, chlorpromazine and triﬂuoperazine) and
second-generation agents (olanzapine, quetiapine and
risperidone). We determined the average daily dose pre-
scribed for each antipsychotic during the follow-up
period, as well as the length of time for which antipsy-
chotics had been prescribed. We did this by using data
on the strength of the antipsychotics prescribed, the
total amount prescribed and the dose per day. From this
information, it was possible to calculate the total possible
milligram per prescription. These were cumulated for all
prescriptions of a given antipsychotic. The period of
time on a given antipsychotic was calculated using the
ﬁrst and last prescription dates, adding the number of
days the ﬁnal prescription was expected to last, if it were
to be taken as directed. We excluded the total daily
doses, which were implausibly high for community
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prescribing of antipsychotics, since these were likely to
represent erroneous entries. We deﬁned the upper
threshold at twice the maximum recommended daily
dose in the BNF,12 namely over 60 mg for haloperidol,
over 2000 mg for chlorpromazine, over 120 mg for tri-
ﬂuoperazine, over 40 mg for olanzapine, over 1500 mg
for quetiapine and over 32 mg for risperidone. Relatively
few (221) prescriptions were excluded for this reason.
Mental health conditions
We deﬁned severe mental illness as schizophrenia-like
disorders, bipolar-affective disorders and other non-
organic psychoses such as delusional disorder, ‘psychoses
not otherwise speciﬁed’ and severe depression with
psychoses (see online supplementary appendix 1). Read
codes for SMI diagnoses have been previously been vali-
dated.16 We identiﬁed an additional category for people
who were included on the practice’s SMI register
without having a Read code for the SMI diagnoses above
(a general practitioner (GP) SMI register is required as
part of the GP contract in the UK since 2004). Hardoon
et al17 determined that the prevalence of SMI in THIN is
similar to that of epidemiological studies.
Next, we identiﬁed common mental health conditions
for which antipsychotics might be prescribed off-label,
using diagnostic Read code lists, compiled by two clinical
academics, a GP and a psychiatrist.18 These non-SMI con-
ditions comprised depression, anxiety disorders, sleep dis-
orders (insomnia, non-speciﬁc sleep disorders, apnoea,
hypersomnia), dementia, attention deﬁcit and hyperactiv-
ity disorder, personality disorders, post-traumatic stress dis-
order and OCD. These have not been validated; however,
we have reported on trends in anxiety and depression
symptoms and diagnoses as recorded in THIN.19 20
We created a diagnostic hierarchy for people with
more than one mental health diagnosis in their clinical
notes. Hence, if a patient ever had an SMI diagnosis, we
considered this as an indication for antipsychotics.
However, if there was no SMI diagnosis, then all
non-SMI diagnoses were extracted and included in this
study. In other words, the non-SMI diagnoses were not
mutually exclusive; hence, a person could be counted
both as a case of anxiety and as a case of OCD.
Statistical analysis
We calculated the rates of prescribing any antipsychotics,
per 100 000 person years at risk (PYAR). We then calcu-
lated the rates of any ﬁrst-generation or second-
generation antipsychotics, after which we determined
the rates of prescribing individual agents for the three
most commonly prescribed ﬁrst-generation and second-
generation antipsychotic agents. Multivariable Poisson
regression was used to determine associations between
sex, age group, Townsend deprivation quintile, calendar
year and (1) overall antipsychotic prescribing, (2) all
ﬁrst-generation and second-generation antipsychotic
agents and (3) the six most commonly prescribed indi-
vidual antipsychotics. For these analyses, we deﬁned the
population at risk as the total population registered with
the general practices in the period 2007–2011.
We calculated the frequencies (%) for each indication
(diagnosis) and for each of the six most commonly pre-
scribed antipsychotics. We also calculated the median
(IQR) daily dose in milligrams and the length of time
prescribed for a given antipsychotic within three groups:
the SMI (psychosis/bipolar) subgroup, the group with
non-SMI diagnoses and the group with no record of
these diagnoses.
All analyses were carried out using Stata V.13.21
RESULTS
We identiﬁed 47 724 eligible individuals who were pre-
scribed antipsychotic medications. Of these, 13 941 were
solely prescribed ﬁrst-generation antipsychotics; 27 966
were prescribed second-generation antipsychotics; and
5817 received both classes of agents during their follow-up
period (ﬁgure 1). The median length of follow-up for
people receiving any antipsychotic was 2.4 years (IQR
1.3–4.1). The length of the follow-up was slightly longer
for those receiving both ﬁrst-generation and second-
generation antipsychotics (3 years; IQR 1.7–4.7).
Rates of antipsychotic prescribing by sociodemographic
characteristics and over time
Overall, 1% of individuals received an antipsychotic at
some time over the study period. For women, the rate of
prescribing any antipsychotic was 699/100 000 PYAR
(95% CI 693 to 705) as compared to 612/100 000 PYAR
(95% CI 607 to 617) for men. Individuals aged above
80 years were more likely to receive antipsychotics
(Incidence rate ratio (IRR) 2.234; 95% CI 2.222 to 2.246
as compared with those aged 40–49 years). In contrast,
those under the age of 18 and those aged between 18
and 29 were much less likely to receive antipsychotics
(table 1). Those living in the most deprived areas were
more than three times as likely to receive antipsychotics
as those in the least-deprived areas (IRR 3.587 (95% CI
3.567 to 3.606; table 1). These patterns were also
observed when the subgroups that had been prescribed
ﬁrst-generation and second-generation antipsychotics
were examined separately (table 1).
The three most commonly prescribed ﬁrst-generation
antipsychotics were haloperidol, chlorpromazine and tri-
ﬂuoperazine, while olanzapine, risperidone and quetia-
pine were the most commonly issued second-generation
agents (tables 2 and 3). The rates of prescribing these
individual agents followed patterns similar to the aggre-
gate results in terms of their distributions by age and
deprivation. Haloperidol and triﬂuoperazine were more
commonly prescribed to women, as was quetiapine,
while the rates of prescribing risperidone and olanza-
pine were lower in women. Few under-18s received anti-
psychotics, but compared to other agents, risperidone
was prescribed far more commonly to this young age
group (table 3). Over the ﬁve years of the study (2007–
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2011), the rates of prescribing for each ﬁrst-generation
agent decreased, while quetiapine prescription rates
increased the most over time. For example, IRR for tri-
ﬂuoperazine in 2011 (reference category is 2007) was
0.665 (95% CI 0.645 to 0.685) and IRR for quetiapine in
2011 (reference category is 2007) was 1.480 (95% CI
1.463 to 1.497). There was a smaller increase in the rates
of prescriptions for risperidone and olanzapine
(table 3).
Records of mental health conditions in people
prescribed antipsychotics
For people prescribed the three most common ﬁrst-
generation antipsychotics, the proportion with a Read
code for SMI (psychotic or bipolar disorder) varied
between 27% (n=1331) for haloperidol and 35%
(n=1545) for chlorpromazine (table 4). The most
common diagnosis was schizophrenia and related condi-
tions. For second-generation antipsychotics, only 36%
(n=4824) of those prescribed quetiapine had an SMI
record, compared to 46% (n=4597) of those receiving ris-
peridone and 62% (n=7094) of those receiving olanza-
pine (table 4). More than half of the people receiving
ﬁrst-generation antipsychotics had no SMI diagnosis
recorded in their notes, but they did have a code for one
of the non-SMI mental health conditions. The most
common conditions were anxiety, depression and sleep
disorders. Almost one-third of the people receiving halo-
peridol had a record of dementia. For second-generation
agents, the proportions with non-SMI diagnoses were
similar, although the number of people with a record of
dementia was highest for quetiapine (26% of prescrip-
tions). Between 12% and 17% of the people who had
been prescribed ﬁrst-generation agents had no record of
an SMI or of any non-SMI mental health diagnosis.
The median daily dose for antipsychotics was higher
in those who did have an SMI diagnosis, and was highest
among those with records of schizophrenia (table 5).
Within the non-SMI groups, the median daily doses were
similar, although the highest doses were observed in
people with a record of a sleep disorder or a personality
disorder. The longest durations of antipsychotic treat-
ment were generally observed in people with a diagnosis
of schizophrenia or in those who were included on the
SMI register in general practice (see online supplemen-
tary table S1). Within the non-SMI group, the duration
of treatment showed little variation between diagnoses,
although the median length of treatment seemed
longest in people with dementia or attention deﬁcit
hyperactivity disorder (ADHD).
Figure 1 Flow of individuals
through the study. FGA, first
generation antipsychotics; SGA,
second generation antipsychotics.
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Table 1 Rates of antipsychotic prescribing by class of antipsychotic, age gender and social deprivation
Any antipsychotic Any first-generation antipsychotic Any second-generation antipsychotic
First-generation and second-generation
antipsychotics
Rate per
100 000 PYAR 95% CI IRR* 95% CI
Rate per
100 000 PYAR 95% CI IRR* 95% CI
Rate per
100 000 PYAR 95% CI IRR* 95% CI
Rate per
100 000 PYAR 95% CI IRR* 95% CI
Male 612 (607 to 617) 1.000 197 (194 to 200) 1.000 458 (454 to 462) 1.000 43 (41 to 44) 1.000
Female 699 (693 to 705) 1.092 (1.088 to 1.095) 256 (253 to 259) 1.204 (1.196 to 1.211) 489 (484 to 493) 1.050 (1.046 to 1.054) 46 (44 to 47) 1.010 (1.096 to 1.103)
Under 18 63 (61 to 66) 0.044 (0.044 to 0.045) 5 (4 to 5) 0.009 (0.008 to 0.009) 59 (57 to 62) 0.058 (0.057 to 0.059) 0.6 (0.4 to 0.9) 0.026 (0.026 to 0.027)
18–29 459 (451 to 467) 0.351 (0.349 to 0.353) 111 (107 to 115) 0.223 (0.220 to 0.227) 376 (369 to 383) 0.401 (0.398 to 0.404) 28 (26 to 30) 0.348 (0.346 to 0.351)
30–39 817 (806 to 828) 0.804 (0.799 to 0.808) 238 (232 to 244) 0.643 (0.636 to 0.650) 638 (628 to 648) 0.867 (0.861 to 0.872) 58 (56 to 62) 0.803 (0.799 to 0.807)
40–49 852 (842 to 863) 1.000 289 (283 to 295) 1.000 628 (619 to 637) 1.000 64 (62 to 67) 1.000
50–59 712 (701 to 723) 0.872 (0.867 to 0.877) 283 (276 to 290) 1.045 (1.035 to 1.056) 483 (474 to 492) 0.804 (0.799 to 0.809) 54 (51 to 57) 0.872 (0.867 to 0.877)
60–69 642 (631 to 653) 0.824 (0.819 to 0.829) 281 (274 to 289) 1.039 (1.029 to 1.050) 406 (398 to 415) 0.740 (0.735 to 0.745) 46 (43 to 49) 0.824 (0.819 to 0.829)
70–79 842 (827 to 857) 0.973 (0.967 to 0.980) 350 (341 to 360) 1.192 (1.179 to 1.205) 546 (534 to 559) 0.888 (0.881 to 0.894) 54 (51 to 58) 0.971 (0.965 to 0.977)
80+ 2201 (2170 to 2231) 2.234 (2.222 to 2.246) 793 (775 to 811) 2.358 (2.334 to 2.382) 1529 (1504 to 1555) 2.185 (2.171 to 2.199) 121 (114 to 129) 2.221 (2.209 to 2.234)
Townsend
Least deprived 403 (398 to 409) 1.000 138 (135 to 142) 1.000 291 (286 to 296) 1.000 26 (24 to 27) 1.000
2 499 (492 to 506) 1.211 (1.203 to 1.218) 180 (176 to 184) 1.251 (1.237 to 1.265) 351 (345 to 357) 1.194 (1.186 to 1.203) 33 (31 to 35) 1.214 (1.207 to 1.222)
3 645 (637 to 653) 1.707 (1.697 to 1.716) 223 (218 to 228) 1.764 (1.745 to 1.782) 465 (458 to 472) 1.683 (1.672 to 1.695) 43 (41 to 45) 1.714 (1.705 to 1.724)
4 844 (834 to 854) 2.457 (2.443 to 2.470) 295 (290 to 301) 2.516 (2.491 to 2.542) 608 (600 to 616) 2.432 (2.416 to 2.448) 59 (57 to 62) 2.476 (2.463 to 2.489)
Most deprived 1158 (1145 to 1172) 3.587 (3.567 to 3.606) 386 (378 to 394) 3.649 (3.612 to 3.686) 853 (841 to 865) 3.560 (3.537 to 3.583) 80 (76 to 84) 3.613 (3.593 to 3.633)
Missing 806 (781 to 830) 2.282 (2.259 to 2.305) 270 (256 to 284) 2.360 (2.315 to 2.406) 586 (566 to 608) 2.250 (2.223 to 2.277) 51 (45 to 57) 2.187 (2.165 to 2.210)
Year
2007 591 (584 to 599) 1.000 236 (231 to 241) 1.000 399 (393 to 405) 1.000 44 (42 to 46) 1.000
2008 654 (646 to 663) 1.075 (1.069 to 1.080) 243 (238 to 248) 0.990 (0.981 to 1.000) 456 (449 to 463) 1.118 (1.111 to 1.125) 45 (43 to 47) 1.075 (1.070 to 1.081)
2009 679 (670 to 687) 1.110 (1.104 to 1.115) 237 (232 to 242) 0.946 (0.938 to 0.955) 487 (480 to 494) 1.194 (1.186 to 1.201) 45 (43 to 47) 1.108 (1.102 to 1.114)
2010 718 (710 to 727) 1.151 (1.145 to 1.157) 227 (222 to 232) 0.880 (0.872 to 0.888) 536 (529 to 543) 1.290 (1.282 to 1.298) 44 (42 to 47) 1.147 (1.141 to 1.153)
2011 637 (629 to 646) 1.065 (1.059 to 1.071) 189 (184 to 193) 0.745 (0.737 to 0.752) 492 (484 to 499) 1.230 (1.222 to 1.238) 43 (41 to 45) 1.055 (1.050 to 1.061)
*All IRR are adjusted for the other characteristics in this table.
IRR, incident rate ratio; PYAR, person years at risk.
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Table 2 Rates of antipsychotic prescribing for the three most commonly prescribed first-generation antipsychotics
Characteristic
Haloperidol Chlorpromazine Trifluoperazine
Rate per
100 000
PYAR 95% CI IRR* 95% CI
Rate per
100 000
PYAR 95% CI IRR* 95% CI
Rate per
100 000
PYAR 95% CI IRR* 95% CI
Male 42 (41 to 44) 1.000 51 (50 to 53) 1.000 22 (21 to 23) 1.000
Female 55 (54 to 57) 1.123 (1.107 to 1.138) 52 (50 to 53) 1.121 (1.107 to 1.135) 36 (35 to 38) 1.577 (1.547 to 1.607)
Under 18 1 (1 to 2) 0.017 (0.015 to 0.019) 0.6 (0.4 to 0.9) 0.004 (0.003 to 0.004) 0.6 (0.4 to 0.9) 0.006 (0.005 to 0.008)
18–29 16 (15 to 18) 0.204 (0.196 to 0.213) 33 (31 to 35) 0.231 (0.225 to 0.237) 13 (12 to 15) 0.195 (0.186 to 0.205)
30–39 35 (33 to 38) 0.659 (0.641 to 0.678) 72 (68 to 75) 0.640 (0.628 to 0.653) 30 (28 to 32) 0.634 (0.613 to 0.655)
40–49 42 (40 to 44) 1.000 85 (82 to 89) 1.000 37 (35 to 40) 1.000
50–59 44 (42 to 47) 1.085 (1.058 to 1.112) 77 (74 to 81) 0.992 (0.974 to 1.010) 38 (35 to 40) 1.046 (1.015 to 1.078)
60–69 51 (48 to 54) 1.175 (1.145 to 1.205) 63 (60 to 67) 0.822 (0.806 to 0.839) 46 (43 to 49) 1.378 (1.339 to 1.419)
70–79 98 (93 to 104) 2.123 (2.073 to 2.175) 54 (50 to 58) 0.613 (0.598 to 0.629) 54 (50 to 58) 1.739 (1.687 to 1.792)
80+ 330 (319 to 342) 5.833 (5.710 to 5.958) 58 (53 to 63) 0.595 (0.578 to 0.614) 72 (67 to 78) 1.868 (1.808 to 1.931)
Townsend
Least deprived 32 (30 to 33) 1.000 24 (22 to 25) 1.000 19 (18 to 21) 1.000
2 48 (46 to 50) 1.499 (1.464 to 1.534) 33 (32 to 35) 1.225 (1.194 to 1.257) 22 (20 to 23) 1.185 (1.146 to 1.225)
3 53 (51 to 56) 1.914 (1.871 to 1.957) 46 (44 to 48) 2.117 (2.068 to 2.167) 28 (27 to 30) 1.809 (1.754 to 1.867)
4 60 (58 to 63) 2.360 (2.307 to 2.413) 68 (65 to 71) 3.131 (3.062 to 3.202) 39 (37 to 41) 2.839 (2.756 to 2.925)
Most deprived 62 (58 to 65) 2.666 (2.603 to 2.731) 116 (112 to 120) 5.743 (5.619 to 5.870) 50 (47 to 53) 3.703 (3.591 to 3.818)
Missing 49 (43 to 56) 2.315 (2.217 to 2.417) 95 (86 to 103) 4.103 (3.961 to 4.250) 30 (26 to 35) 2.113 (1.987 to 2.246)
Year
2007 51 (49 to 54) 1.000 58 (55 to 60) 1.000 33 (31 to 35) 1.000
2008 54 (52 to 56) 1.019 (0.998 to 1.039) 56 (54 to 59) 0.973 (0.955 to 0.992) 31 (29 to 32) 0.941 (0.916 to 0.967)
2009 52 (50 to 54) 0.955 (0.936 to 0.974) 53 (51 to 56) 0.899 (0.882 to 0.916) 29 (27 to 31) 0.899 (0.874 to 0.924)
2010 48 (46 to 50) 0.822 (0.805 to 0.840) 47 (45 to 49) 0.824 (0.807 to 0.840) 30 (28 to 32) 0.901 (0.876 to 0.926)
2011 39 (37 to 41) 0.684 (0.669 to 0.700) 44 (41 to 46) 0.751 (0.736 to 0.766) 24 (22 to 26) 0.665 (0.645 to 0.685)
*All IRR are adjusted for the other characteristics in this table.
IRR, incident rate ratio; PYAR, person years at risk.
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Table 3 Rates of antipsychotic prescribing for the three most commonly prescribed second-generation antipsychotics
Characteristic
Olanzapine Quetiapine Risperidone
Rate per
100 000
PYAR 95% CI IRR* 95% CI
Rate per
100 000
PYAR 95% CI IRR* 95% CI
Rate per
100 000
PYAR 95% CI IRR* 95% CI
Male 168 (166 to 171) 1.000 120 (117 to 122) 1.000 137 (134 to 139) 1.000
Female 139 (136 to 141) 0.835 (0.830 to 0.841) 197 (194 to 199) 1.542 (1.531 to 1.553) 115 (113 to 117) 0.854 (0.847 to 0.861)
Under 18 3 (2 to 4) 0.008 (0.008 to 0.009) 3 (3 to 4) 0.012 (0.012 to 0.013) 50 (47 to 52) 0.196 (0.193 to 0.200)
18–29 133 (129 to 137) 0.349 (0.345 to 0.354) 106 (102 to 110) 0.418 (0.412 to 0.424) 116 (112 to 121) 0.484 (0.477 to 0.491)
30–39 243 (237 to 249) 0.822 (0.813 to 0.830) 192 (186 to 197) 0.941 (0.929 to 0.952) 155 (150 to 160) 0.810 (0.799 to 0.820)
40–49 249 (243 to 255) 1.000 175 (170 to 180) 1.000 158 (154 to 163) 1.000
50–59 192 (187 to 198) 0.868 (0.859 to 0.877) 128 (124 to 133) 0.730 (0.720 to 0.740) 131 (127 to 136) 0.845 (0.834 to 0.857)
60–69 154 (149 to 160) 0.781 (0.772 to 0.790) 109 (105 to 114) 0.670 (0.660 to 0.679) 116 (111 to 120) 0.819 (0.808 to 0.831)
70–79 140 (134 to 146) 0.673 (0.663 to 0.683) 226 (219 to 235) 1.263 (1.247 to 1.280) 124 (118 to 130) 0.772 (0.760 to 0.785)
80+ 195 (186 to 204) 0.841 (0.829 to 0.854) 891 (871 to 910) 4.473 (4.427 to 4.520) 289 (278 to 300) 1.629 (1.606 to 1.653)
Townsend
Least deprived 81 (78 to 84) 1.000 111 (108 to 114) 1.000 79 (76 to 81) 1.000
2 101 (98 to 104) 1.314 (1.296 to 1.332) 130 (126 to 134) 1.113 (1.100 to 1.126) 93 (90 to 96) 1.157 (1.141 to 1.174)
3 140 (137 to 144) 1.898 (1.873 to 1.922) 164 (160 to 168) 1.497 (1.480 to 1.514) 121 (117 to 124) 1.614 (1.593 to 1.636)
4 211 (206 to 216) 3.122 (3.084 to 3.160) 192 (187 to 196) 1.963 (1.941 to 1.984) 163 (159 to 168) 2.297 (2.267 to 2.327)
Most deprived 320 (313 to 328) 4.956 (4.897 to 5.016) 239 (232 to 245) 2.663 (2.633 to 2.693) 227 (221 to 233) 3.243 (3.201 to 3.285)
Missing 200 (188 to 212) 2.821 (2.761 to 2.882) 196 (185 to 209) 1.974 (1.933 to 2.016) 148 (138 to 159) 1.981 (1.933 to 2.031)
Year
2007 140 (137 to 144) 1.000 117 (113 to 120) 1.000 118 (114 to 121) 1.000
2008 153 (149 to 157) 1.050 (1.039 to 1.062) 144 (140 to 148) 1.224 (1.209 to 1.238) 124 (121 to 128) 1.050 (1.037 to 1.064)
2009 157 (153 to 161) 1.088 (1.076 to 1.100) 165 (161 to 170) 1.360 (1.344 to 1.376) 124 (120 to 128) 1.053 (1.040 to 1.066)
2010 166 (162 to 170) 1.145 (1.133 to 1.158) 190 (186 to 195) 1.523 (1.506 to 1.541) 138 (134 to 142) 1.103 (1.089 to 1.117)
2011 151 (147 to 155) 1.077 (1.065 to 1.089) 177 (173 to 181) 1.480 (1.463 to 1.497) 125 (121 to 129) 1.040 (1.026 to 1.053)
*All IRR are adjusted for the other characteristics in this table.
IRR, incident rate ratio; PYAR, person years at risk.
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Table 4 Diagnosis by the three most commonly prescribed first-generation and second-generation antipsychotics 2007–2011
Diagnosis
Haloperidol
(N=4913)
Chlorpromazine
(N=4404)
Trifluoperazine
(N=2633)
Olanzapine
(N=11 502)
Quetiapine
(N=13 326)
Risperidone
(N=9956)
n Per cent n Per cent n Per cent n Per cent n Per cent n Per cent
SMI*
Any SMI diagnosis 1331 27 1545 35 783 30 7094 62 4824 36 4597 46
Schizophrenia 620 13 633 14 359 14 3060 27 1489 11 2143 22
Bipolar disorder 298 6 343 8 119 5 1655 14 1689 13 726 7
Other SMI 267 5 334 8 203 8 1898 17 1163 9 1291 13
On SMI register only 146 3 235 5 102 4 481 4 483 4 437 4
Non-SMI*
Any non-SMI diagnosis 2762 56 2241 51 1529 58 3753 33 7623 57 4085 41
ADHD 36 0.7 33 0.7 10 0.4 75 0.7 77 0.6 538 5
Anxiety 783 16 1124 26 909 35 1779 15 2669 20 1391 14
Depression 1330 27 1748 40 1142 43 2964 26 4648 35 2204 22
Dementia 1521 31 183 4 157 6 466 4 3514 26 1211 12
OCD 40 0.8 93 2 47 2 216 2 250 2 221 2
PD 136 3 294 7 122 4 525 5 705 5 349 4
PTSD 37 0.8 97 2 29 1 197 2 210 2 94 0.9
Sleep disorders 761 15 815 19 511 19 1124 10 1926 14 1078 11
None of the above* 820 17 618 14 321 12 655 6 879 7 1274 13
*If a person has an SMI diagnosis, any non-SMI diagnoses will not be included in the numbers below. For those who do not have an SMI diagnosis, all non-SMI diagnoses will be shown (ie,
they are not mutually exclusive). ‘None of the above’ means not having an SMI diagnosis or any of the non-SMI diagnoses in the table.
ADHD, attention deficit hyperactivity disorder; OCD, obsessive compulsive disorder; PD, personality disorder; PTSD, post-traumatic stress disorder; SMI, serious mental illness.
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DISCUSSION
In this study of antipsychotic prescribing in a large
primary care database representative of the UK, approxi-
mately half of the prescriptions for ﬁrst-generation and
second-generation antipsychotics are issued to people
who have no record of SMI, deﬁned as schizophrenia,
bipolar affective disorder or other non-organic psychosis
in their clinical notes. Furthermore, they are more likely
to be prescribed to older people who may be more sensi-
tive to adverse effects such as movement disorders and
cardiometabolic risk. When antipsychotics are pre-
scribed to people without SMI, they tend to be given in
lower doses and for slightly shorter periods, with the
exception of people with ADHD and dementia who
receive these drugs for relatively long periods.
Other studies on antipsychotic prescribing relate to an
earlier time period prior to the introduction of anti-
psychotic guidelines in the UK.22 23 The pattern of pre-
scribing since then has changed over time, 24 with
approximately two-thirds of prescriptions in the current
study being for second-generation antipsychotics.
For the ﬁrst-generation agents, the most common
‘non-SMI’ mental health diagnoses that we identiﬁed
were anxiety, depression, sleep disorders and dementia
(especially for haloperidol). For the second-generation
agents, the same mental health diagnoses were common
including dementia, despite the fact that second-
generation antipsychotics are not recommended in
people with dementia due to the risk of stroke and
other-cause mortality.1 2 Reducing the potential harm
associated with antipsychotics in dementia has been
emphasised as a priority by organisations such as the
Department of Health in England and the US Food and
Drug Administration.25 26 Our ﬁndings suggest that
further effort is required to decrease primary care anti-
psychotic prescriptions in dementia and that assessing
time trends in antipsychotic prescribing in this group is
an important area for future research.
The median daily doses and duration of treatment with
antipsychotics tended to be slightly greater in people with
SMI diagnoses (especially schizophrenia); however,
people with depression, anxiety, personality and sleep dis-
orders still received substantial doses of these agents for
relatively long periods of time. For instance, the median
daily dose of olanzapine prescribed to people with sleep
disorders was 10 mg/day, the same daily dose as pre-
scribed to people with a diagnosis of bipolar disorder and
only slightly less than the average dose of 12 mg/day pre-
scribed to people with schizophrenia (table 5). Within
the non-SMI group, the median doses of risperidone and
quetiapine were also the highest in those with sleep disor-
ders, post-traumatic stress disorder and personality dis-
order. While the median dose is a crude method of
quantifying the amount prescribed for each indication
explored in this paper, it does allow us to make compari-
sons between these diagnoses.
There are a number of possible explanations for the
high rates of antipsychotic prescribing to people without
Ta
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a psychosis diagnosis. First, it may be that the clinician
prescribes antipsychotics because the person does have
psychotic symptoms, but the clinician does not assign a
label of schizophrenia or other psychosis, either due to
patient preference or to avoid the associated stigma with
such labels. However, this would suggest that there are
large numbers of people with unrecorded psychosis
and/or bipolar disorder in primary care. This is not con-
sistent with other researches in UK primary care data-
bases which have shown that rates of schizophrenia and
bipolar disorder recorded in the database are similar to
those in other epidemiological studies.17 Therefore, it
seems unlikely that large numbers of people in primary
care have psychosis without a corresponding record.
Second, it is possible that in real-life practice, antipsy-
chotics are prescribed quite commonly to people with
problems related to depression, anxiety, sleep, dementia
and other conditions; despite guidelines recommending
caution and only suggesting this as a strategy in the treat-
ment of unresponsive cases.3 6 It may be that clinicians
and/or mental health professionals quite frequently add
antipsychotics to the treatment plan for people with
non-psychotic disorders, either for agitation, poor sleep
or anxiety or due to their general reputation as tranquil-
lising medications. Since there were no major differ-
ences in the median doses and duration of treatment
according to the likely indication, these patterns of pre-
scribing warrant some attention in terms of monitoring
side effects particularly weight gain, extra-pyramidal side
effects and metabolic impacts such as hyperprolactinae-
mia, glucose dysregulation and effects on lipid proﬁles.
The current UK policy only recommends physical moni-
toring for people whom the general practice includes
on its SMI register. It may be that this recommendation
should be extended to all people prescribed antipsycho-
tics in primary care.
Strengths and limitations
The primary care databases allow us to study large repre-
sentative samples of patients in general practice across
the UK. THIN has a good record of prescriptions issued
and a comparison with dispensing data suggests that the
majority of its prescriptions issued are collected,27 but of
course this may not mean that patients have been actu-
ally taking the medication. Primary care diagnoses of
SMIs have been validated;16 however, this is not the case
for some other conditions that had been explored such
as ADHD and OCD.
Research with routine clinical data has its limitations;
for instance, we could not perform a more detailed
assessment of patient characteristics and preferences
which may inﬂuence treatment decisions. For non-SMI
diagnoses such as depression and anxiety, we extracted
all diagnoses which had been entered at any time. We
did this because GPs do not routinely re-enter diagnoses
at each subsequent appointment and we wanted to
capture all relevant information regarding the possible
indication. A limitation of this method, and of the
database, is that we cannot be certain that the decision
to prescribe had been temporally related to the mental
health condition entered at another time. However, this
method does give an indication of the long-term clinical
presentation of people without an SMI Read code who
have been prescribed antipsychotics. It would be useful
to explore the reasons underpinning these high rates of
prescribing to groups not traditionally thought eligible
for antipsychotic treatment. This might require primary
research studies interviewing clinicians and reviewing
individual patients. However, further database work
could explore symptoms associated with these anti-
psychotic prescriptions, and the treatment decisions pre-
dating the choice of an antipsychotic agent. Also, the
same databases could be used to assess how frequently
cardiovascular risk factors are measured in this popula-
tion, especially body mass index, cholesterol and high-
density lipoprotein (HDL) cholesterol, as well as giving
some indication of glucose regulation such as HbA1c,
random or fasting glucose.
We need to know more about co-prescribing in the
people without a diagnosis of psychosis or bipolar dis-
order, for instance, benzodiazepines and mood stabili-
sers. We also need to quantify the degree of beneﬁt or
harm that may be associated with using such treatments.
To what degree do they cause physical and/or mental
health problems for the recipients, and to what extent
do they lead to symptom remission? A meta-analysis of
antipsychotic drugs in major depressive disorder found
that although these agents may improve depression
symptoms, they have no impact on the functioning or
quality of life.28 The few existing randomised controlled
trials involving people with personality disorders have
shown little beneﬁt of antipsychotics over placebo.6 29
Finally, it is important to explore whether these agents
are discontinued following amelioration of any mental
health problem for which they are chosen, and to assess
the risks and beneﬁts of stopping such agents in differ-
ent diagnostic groups.
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